Terms: = Thyroid cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Diagnosis
32 results:
1. Simultaneous Presentation of Secondary Adrenal Insufficiency and Primary Hypothyroidism due to Pembrolizumab: A Case Report.
Khatri S; Alom M; Kashfi S; Atallah J; Goswami G
J Investig Med High Impact Case Rep; 2023; 11():23247096231194401. PubMed ID: 37642143
[TBL] [Abstract] [Full Text] [Related]
2. PD-L1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma.
Zantut-Wittmann DE; Barreto IS; Laus AC; Moreno DA; Moma CA; Maia FFR; Assumpção LVMD; Reis RM
Mol Cell Endocrinol; 2023 Jun; 570():111931. PubMed ID: 37072108
[TBL] [Abstract] [Full Text] [Related]
3. Top Ten Tips Palliative Care Clinicians Should Know About Managing Immune-Mediated Endocrine Toxicities in cancer.
Ferreira MN; Rao M; Kamal AH; Shariff A
J Palliat Med; 2022 Nov; 25(11):1715-1720. PubMed ID: 35696238
[TBL] [Abstract] [Full Text] [Related]
4. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
Front Immunol; 2022; 13():779691. PubMed ID: 35558065
[TBL] [Abstract] [Full Text] [Related]
5. [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
Santos MJ
Acta Med Port; 2022 Mar; 35(3):209-215. PubMed ID: 35077347
[TBL] [Abstract] [Full Text] [Related]
6. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.
Hribernik N; Huff DT; Studen A; Zevnik K; Klaneček Ž; Emamekhoo H; Škalic K; Jeraj R; Reberšek M
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1857-1869. PubMed ID: 34958422
[TBL] [Abstract] [Full Text] [Related]
7. Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis.
Seejore K; Giannoudi M; Osborn D; Lynch JM; Al-Qaissi A; Dunwoodie E; Hook J; Marples M; Murray RD
Eur J Endocrinol; 2021 Dec; 186(1):83-93. PubMed ID: 34735371
[TBL] [Abstract] [Full Text] [Related]
8. Programmed cell death protein-1 inhibitors in the treatment of digestive system tumors in Chinese population: an observational study of effectiveness and safety.
Yang W; Chang L; Guo Q; Chen J; Yu W; Zhang W
Ann Palliat Med; 2021 Aug; 10(8):9015-9024. PubMed ID: 34488388
[TBL] [Abstract] [Full Text] [Related]
9. T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis.
Zhu C; Dai Y; Zhang H; Ruan Y; Zhou Y; Dai Y; Fan L; Jia T; Lu H; Chen Q
Diagn Pathol; 2021 Aug; 16(1):84. PubMed ID: 34465342
[TBL] [Abstract] [Full Text] [Related]
10. The value of the Demetics ultrasound-assisted diagnosis system in the differential diagnosis of benign from malignant thyroid nodules and analysis of the influencing factors.
Mai W; Zhou M; Li J; Yi W; Li S; Hu Y; Ji J; Zeng W; Gao B; Liu H
Eur Radiol; 2021 Oct; 31(10):7936-7944. PubMed ID: 33856523
[TBL] [Abstract] [Full Text] [Related]
11. [A Case of thyroid Dysfunction and Isolated Adrenocorticotropin Deficiency after Nivolumab Therapy for Malignant Melanoma].
Nishio K; Okada Y; Kurozumi A; Tanaka Y
J UOEH; 2021; 43(1):97-102. PubMed ID: 33678791
[TBL] [Abstract] [Full Text] [Related]
12. Genetic variants and risk of thyroid cancer among Iranian patients.
Jamshidi M; Farnoosh G; Mohammadi Pour S; Rafiee F; Saeedi Boroujeni A; Mahmoudian-Sani MR
Horm Mol Biol Clin Investig; 2021 Feb; 42(2):223-234. PubMed ID: 33544997
[TBL] [Abstract] [Full Text] [Related]
13. From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer.
D'Andréa G; Lassalle S; Guevara N; Mograbi B; Hofman P
Theranostics; 2021; 11(3):1310-1325. PubMed ID: 33391536
[TBL] [Abstract] [Full Text] [Related]
14. [Endocrine side effects of cancer immunotherapy].
Kroiß M; Schilling B; Deutschbein T
Dtsch Med Wochenschr; 2020 Dec; 145(24):1736-1741. PubMed ID: 33254246
[TBL] [Abstract] [Full Text] [Related]
15. Immune-related adverse events in patients with solid-organ tumours treated with immunotherapy: a 3-year study of 102 cases from a single centre.
Gonzalez-Mazón I; Sánchez-Bilbao L; Martín-Varillas JL; García-Castaño A; Delgado-Ruiz M; Bernat Piña I; Hernández JL; Castañeda S; Llorca J; González-Gay MA; Blanco R
Clin Exp Rheumatol; 2021; 39(3):612-620. PubMed ID: 32896258
[TBL] [Abstract] [Full Text] [Related]
16. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.
Crespo-Rodriguez E; Bergerhoff K; Bozhanova G; Foo S; Patin EC; Whittock H; Buus R; Haider S; Muirhead G; Thway K; Newbold K; Coffin RS; Vile RG; Kim D; McLaughlin M; Melcher AA; Harrington KJ; Pedersen M
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32759235
[TBL] [Abstract] [Full Text] [Related]
17. Immunoassay Interference on thyroid Function Tests During Treatment with Nivolumab.
Paragliola RM; Corsello A; Papi G; Melfa E; Urbani A; Pontecorvi A; Corsello SM; Carrozza C
Thyroid; 2020 Jul; 30(7):1091-1094. PubMed ID: 32122271
[No Abstract] [Full Text] [Related]
18. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
Kurimoto C; Inaba H; Ariyasu H; Iwakura H; Ueda Y; Uraki S; Takeshima K; Furukawa Y; Morita S; Yamamoto Y; Yamashita S; Katsuda M; Hayata A; Akamatsu H; Jinnin M; Hara I; Yamaue H; Akamizu T
Cancer Sci; 2020 May; 111(5):1468-1477. PubMed ID: 32086984
[TBL] [Abstract] [Full Text] [Related]
19. Estimating the Growth Rate of Lung Metastases in Differentiated thyroid Carcinoma: Response Evaluation Criteria in Solid Tumors or Doubling Time?
Song E; Ahn J; Jeon MJ; Lee SM; Lee JH; Kim TY; Baek JH; Kim WB; Shong YK; Kim WG
Thyroid; 2020 Mar; 30(3):418-424. PubMed ID: 31880976
[No Abstract] [Full Text] [Related]
20. [thyroid dysfunctions secondary to cancer immunotherapy].
Cugnet Anceau C; Abeillon J; Maillet D; Borson-Chazot F; Disse E
Bull Cancer; 2020 Feb; 107(2):262-271. PubMed ID: 31879018
[TBL] [Abstract] [Full Text] [Related]
[Next]
